Proceeds will be used to advance lead program in breast cancer into Phase 1/2 clinical development Financing co-led by BVF Partners L.P., Logos Capital and Janus Henderson Investors SAN FRANCISCO, July 22, 2020-- Olema Oncology, a biopharmaceutical company developing innovative targeted therapies for women's cancers, today announced the closing of an oversubscribed $54 million Series B financing. Proceeds will be used to advance OP-1250, the Company's lead program in breast cancer, into Phase 1/2 clinical development and expand ongoing research and development activities.